Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | ICON: chemotherapy combined with ipilimumab and nivolumab in metastatic HR+ breast cancer

Jon Amund Kyte, University of Oslo, Oslo, Norway discusses the ICON trial (NCT03409198), a randomized Phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab, in metastatic hormone receptor-positive breast cancer (BC) patients. Dr Kyte explains how the host immune response is predictive of chemotherapy efficacy in subgroups of BC patients and the role of ipilimumab in stimulating a patient’s anti-tumor response, in combination with nivolumab. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.